A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist [PDF]
Frontiers in Cardiovascular MedicineMultiple studies have shown that finerenone (BAY 94-8862), a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), possesses different or superior mechanisms of action to traditional MRAs.
Shuhui Zhai +3 more
doaj +4 more sources
Use of nonsteroidal mineralocorticoid receptor antagonist in chronic kidney disease: A case report of a patient with Fabry disease in his mid-20s [PDF]
Journal of International Medical ResearchFabry disease is a rare X-linked lysosomal storage disorder caused by a defect in glycosphingolipid metabolism, which leads to the accumulation of globotriaosylceramide (Gb3) in various cell types.
Guan-Qiang Tian +5 more
doaj +2 more sources
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease [PDF]
Endocrinology and Metabolism, 2023 Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
doaj +2 more sources
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications.
Ixchel Lima Posada +9 more
doaj +2 more sources
Structural Mechanism of a Partial Glucocorticoid Receptor Agonist Functioning as a Mineralocorticoid Receptor Antagonist [PDF]
Structural DynamicsThe Glucocorticoid Receptor (GR) and Mineralocorticoid Receptor (MR) are homologous ligand-activated transcription factors that regulate extensive downstream gene expression networks involved in metabolism, development, electrolyte homeostasis, and ...
Xu Liu
doaj +2 more sources
Finerenone as a Nonsteroidal Mineralocorticoid Receptor Antagonist for Lupus Nephritis [PDF]
Kidney International ReportsMingfang Sun +4 more
doaj +2 more sources
Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors [PDF]
Kidney Research and Clinical Practice, 2022 Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis).
Anthony T. P. Chan, Sydney C. W. Tang
doaj +1 more source
Administration of finerenone in chronic kidney disease [PDF]
Journal of Nephropathology, 2023 Spironolactone is a first-generation and non-selective mineralocorticoid receptor antagonist (MRA). It is extensively well-studied and recommended due to increased accessibility for patients.
Mohsen Akhavan Sepahi +4 more
doaj +1 more source
American Journal of Ophthalmology Case Reports, 2023 Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use.
Mohamad El Wardani, Marc D. de Smet
doaj +1 more source
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study. [PDF]
PLoS ONE, 2014 It has been suggested that mineralocorticoid receptor antagonists have direct cardioprotective properties, because these drugs reduce mortality in patients with heart failure.
T N A van den Berg +5 more
doaj +1 more source